arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Royalty Pharma plc

RPRX
$56.79 ▼ -0.44 (-0.77%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
28 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
88
Health
Excellent
Bullish
auto_awesome

Analytical Summary

Royalty Pharma plc shows strong fundamentals with top-quartile Profit Margin (%) and Operating Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $24.8B
Dividend Yield 0.41%
Revenue Growth 11.0%
Op. Margin 89.3%
ROIC 6.3%
FCF / Share $1.64
Trailing P/E 84.8x
Price / Book
FCF Yield 2.9%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

28-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$630.58M
↑ +11.0%
Net Income Profit after all expenses
$294.69M
↑ +23.6%
Operating Margin Operating profit as % of sales
89.3%
↑ +43.0% 99th
FCF / Share Free cash flow per share
$1.64
↑ +20.1%
Long-Term Debt Long-term obligations
$8.96B
— +0.1%
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
98
Financial Health
75
Cash Quality
92

Dividend History

Dividend / share · sourced from SEC filings
$0.80 Latest / share
+5.3% YoY
+38.7% 4-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 28 quarters